Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …

Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial,
venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or …

Antiphospholipid syndrome, also known as 'Hughes Syndrome', is an autoimmune disease
characterised by a set of clinical manifestations, almost all of which are direct or indirect …

Although the knowledge of APS pathogenesis has grown in recent years, the management
principles and strategies are largely unchanged. There is an unmet need for evaluating …

Stroke survivors carry a high risk of recurrence. Antithrombotic medications are paramount
for secondary prevention and thus crucial to reduce the overall stroke burden. Appropriate …

Anti-phospholipid syndrome (APS) is an acquired pro-thrombotic autoimmune disease that
predisposes to thrombotic events and/or obstetric complications, in the persistent presence …

Antiphospholipid syndrome (APS) is a thromboinflammatory disease with a variety of clinical
phenotypes. Primary thrombosis prophylaxis should take an individualized risk stratification …

Venous thromboembolism (VTE) constitutes a common cause of hospital-related morbidity
and mortality, with the proverbial clinical feature of deep venous thrombosis (DVT) …

Background Antiphospholipid syndrome (APS) is an acquired hypercoagulable condition
associated with antiphospholipid antibody (aPL) presence. Data on re-thrombosis following …

Antiphospholipid syndrome is characterised by recurrent thrombosis (arterial, venous,
microvascular) and/or pregnancy complications in the presence of persistent …